Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Biocon Says Medicine Eased Psoriasis in Late-Stage Trial

Biocon Ltd. said its experimental drug itolizumab met the main goal of a late-stage clinical trial, reducing the severity of psoriasis.

An interim analysis of the 200-person study showed that patients taking the drug had a response rate of 46 percent after 28 weeks, the Bangalore, India-based company said in an e-mailed statement today. The drug was safe and well-tolerated, with an infection rate of about 10 percent, the drugmaker said.

Biocon plans to speed up development of the drug for other autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis, it said. Itolizumab is a so-called monoclonal antibody, which are made in a lab to mimic natural substances that stimulate the human immune system to attack disease-causing cells. Psoriasis is a chronic skin ailment.

“This could possibly become the first novel biologic developed and approved from India and is an important milestone for Biocon,” Chairman Kiran Mazumdar-Shaw said in the statement. “We look forward to taking this molecule to the market across multiple indications with a global partner.”

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.